Nothing but NET: A review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy

Pediatric Blood and Cancer

Volumn 62, Issue 1, 2015, Pages 5-11

  Streby, Keri A ^a   Shah, Nilay ^a   Ranalli, Mark A ^a   Kunkler, Anne ^a   Cripe, Timothy P ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Meta iodobenzylguanidine; Neuroblastoma; Norepinephrine transporter

Indexed keywords

METAIODOBENZAGUANIDINE I 131; NORADRENALIN TRANSPORTER; RADIOPHARMACEUTICAL AGENT; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG; (3 IODOBENZYL)GUANIDINE; RADIOACTIVE IODINE;

CANCER RADIOTHERAPY; DRUG EFFICACY; DRUG RETENTION; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; METABOLISM; PATHOLOGY; PROGNOSIS;

3-IODOBENZYLGUANIDINE; HUMANS; IODINE RADIOISOTOPES; NEUROBLASTOMA; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PROGNOSIS; RADIOPHARMACEUTICALS;

EID: 84922819635     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25200     Document Type: Review

References (99)

1. Castleberry RP. Neuroblastoma. Eur J Cancer 1997; 33:1430-1437 discussion 1437-1438.
2. Matthay KK. Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma. Pediatr Transplant 1999; 3:72-77.
3. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362:2202-2211.
4. Wilson JS, Gains JE, Moroz V, et al. A systematic review of (131)I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer 2014; 50:801-815.
5. Treuner J, Feine U, Niethammer D, et al. Scintigraphic imaging of neuroblastoma with [131-I]iodobenzylguanidine. Lancet 1984; 1:333-334.
6. Dubois SG, Geier E, Batra V, et al. Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group. Int J Mol Imaging 2012; 2012:250834.
7. Carlin S, Mairs RJ, McCluskey AG, et al. Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res 2003; 9:3338-3344.
8. Bönisch H, Brüss M. The norepinephrine transporter in physiology and disease. Handb Exp Pharmacol 2006; 485-524.
9. Iversen ll. The uptake of noradrenaline by the isolated perfused rat heart. Br J Pharmacol Chemother 1963; 21:523-537.
10. Lee KH, Ko BH, Paik JY, et al. Characteristics and regulation of 123I-MIBG transport in cultured pulmonary endothelial cells. J Nucl Med 2006; 47:437-442.
11. Buck J, Bruchelt G, Girgert R, et al. Specific uptake of m-[125I]iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH. Cancer Res 1985; 45:6366-6370.
12. Armour A, Mairs RJ, Gaze MN, et al. Modification of meta-iodobenzylguanidine uptake in neuroblastoma cells by elevated temperature. Br J Cancer 1994; 70:445-448.
13. Smets LA, Loesberg C, Janssen M, et al. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res 1989; 49:2941-2944.
14. Mairs RJ, Gaze MN, Barrett A. The uptake and retention of metaiodobenzyl guanidine by the neuroblastoma cell line NB1-G. Br J Cancer 1991; 64:293-295.
15. Bönisch H, Brüss M. The noradrenaline transporter of the neuronal plasma membrane. Ann N Y Acad Sci 1994; 733:193-202.
16. Kippenberger AG, Palmer DJ, Comer AM, et al. Localization of the noradrenaline transporter in rat adrenal medulla and PC12 cells: evidence for its association with secretory granules in PC12 cells. J Neurochem 1999; 73:1024-1032.
17. Melikian HE, Ramamoorthy S, Tate CG, et al. Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition. Mol Pharmacol 1996; 50:266-276.
18. Nguyen TT, Amara SG. N-linked oligosaccharides are required for cell surface expression of the norepinephrine transporter but do not influence substrate or inhibitor recognition. J Neurochem 1996; 67:645-655.
19. Wieland DM, Mangner TJ, Inbasekaran MN, et al. Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines. J Med Chem 1984; 27:149-155.
20. Mairs RJ, Cunningham SH, Russell J, et al. No-carrier-added iodine-131-MIBG: Evaluation of a therapeutic preparation. J Nucl Med 1995; 36:1088-1095.
21. Taal BG, Hoefnagel C, Boot H, et al. Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice. Ann Oncol 2000; 11:1437-1443.
22. Kölby L, Bernhardt P, Levin-Jakobsen AM, et al. Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Br J Cancer 2003; 89:1383-1388.
23. Nilsson O, Jakobsen AM, Kölby L, et al. Importance of vesicle proteins in the diagnosis and treatment of neuroendocrine tumors. Ann N Y Acad Sci 2004; 1014:280-283.
24. Kölby L, Bernhardt P, Johanson V, et al. Can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant pheochromocytomas? Ann N Y Acad Sci 2006; 1073:491-497.
25. Smets LA, Janssen M, Metwally E, et al. Extragranular storage of the neuron blocking agent meta-iodobenzylguanidine (MIBG) in human neuroblastoma cells. Biochem Pharmacol 1990; 39:1959-1964.
26. Montaldo PG, Lanciotti M, Casalaro A, et al. Accumulation of m-iodobenzylguanidine by neuroblastoma cells results from independent uptake and storage mechanisms. Cancer Res 1991; 51:4342-4346.
27. Gaze MN, Huxham IM, Mairs RJ, et al. Intracellular localization of metaiodobenzyl guanidine in human neuroblastoma cells by electron spectroscopic imaging. Int J Cancer 1991; 47:875-880.
28. Lashford LS, Hancock JP, Kemshead JT. Meta-iodobenzylguanidine (mIBG) uptake and storage in the human neuroblastoma cell line SK-N-BE(2C). Int J Cancer 1991; 47:105-109.
29. Servidei T, Iavarone A, Lasorella A, et al. Release mechanisms of [125I]meta-iodobenzylguanidine in neuroblastoma cells: Evidence of a carrier-mediated efflux. Eur J Cancer 1995; 31A:591-595.
30. Gaze MN, Wheldon TE, O'Donoghue JA, et al. Multi-modality megatherapy with [131I]meta-iodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: Feasibility study of a new strategy for advanced neuroblastoma. Eur J Cancer 1995; 31A:252-256.
31. Shapiro B, Copp JE, Sisson JC, et al. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: Experience in 400 cases. J Nucl Med 1985; 26:576-585.
32. Shapiro B, Sisson JC, Eyre P, et al. 131I-MIBG-a new agent in diagnosis and treatment of pheochromocytoma. Cardiology 1985; 72:137-142.
33. Lewis IJ, Lashford LS, Fielding S, et al. A phase I/II study of 131I mIBG in chemo-resistant neuroblastoma. The United Kingdom Children's Cancer Study Group (UKCCSG). Prog Clin Biol Res 1991; 366:463-469.
34. Voûte PA, Hoefnagel CA, de Kraker J, et al. Results of treatment with 131 I-metaiodobenzylguanidine (131 I-MIBG) in patients with neuroblastoma. Future prospects of zetotherapy. Prog Clin Biol Res 1991; 366:439-445.
35. Matthay KK, DeSantes K, Hasegawa B, et al. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998; 16:229-236.
36. Garaventa A, Bellagamba O, Lo Piccolo MS, et al. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: A mono-institutional experience with 43 patients. Br J Cancer 1999; 81:1378-1384.
37. Castellani MR, Chiti A, Seregni E, et al. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. Q J Nucl Med 2000; 44:77-87.
38. Claudiani F, Stimamiglio P, Bertolazzi L, et al. Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma. Q J Nucl Med 1995; 39:21-24.
39. Kang TI, Brophy P, Hickeson M, et al. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. J Pediatr Hematol Oncol 2003; 25:769-773.
40. Howard JP, Maris JM, Kersun LS, et al. Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer 2005; 44:232-239.
41. Matthay KK, Quach A, Huberty J, et al. Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: A new approaches to neuroblastoma therapy phase I study. J Clin Oncol 2009; 27:1020-1025.
42. Johnson K, McGlynn B, Saggio J, et al. Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma. Pediatr Blood Cancer 2011; 57:1124-1129.
43. Corbett R, Pinkerton R, Tait D, et al. [131I]metaiodobenzylguanidine and high-dose chemotherapy with bone marrow rescue in advanced neuroblastoma. J Nucl Biol Med 1991; 35:228-231.
44. Castel V, Cañete A, Melero C, et al. Results of the cooperative protocol (N-III-95) for metastatic relapses and refractory neuroblastoma. Med Pediatr Oncol 2000; 35:724-726.
45. Matthay KK, Tan JC, Villablanca JG, et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 2006; 24:500-506.
46. Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002; 20:2142-2149.
47. Mastrangelo R, Lasorella A, Troncone L, et al. [131I]metaiodobenzylguanidine in neuroblastoma patients at diagnosis. J Nucl Biol Med 1991; 35:252-254.
48. Mastrangelo S, Tornesello A, Diociaiuti L, et al. Treatment of advanced neuroblastoma: Feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer 2001; 84:460-464.
49. Bleeker G, Schoot RA, Caron HN, et al. Toxicity of upfront (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy in newly diagnosed neuroblastoma patients: A retrospective analysis. Eur J Nucl Med Mol Imaging 2013; 40:1711-1717.
50. De Kraker J, Hoefnagel CA, Caron H, et al. First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma. Eur J Cancer 1995; 31A:600-602.
51. Moyes JS, Babich JW, Carter R, et al. Quantitative study of radioiodinated metaiodobenzylguanidine uptake in children with neuroblastoma: Correlation with tumor histopathology. J Nucl Med 1989; 30:474-480.
52. Bruchelt G, Girgert R, Buck J, et al. Cytotoxic effects of m-[131I]- and m-[125I]iodobenzylguanidine on the human neuroblastoma cell lines SK-N-SH and SK-N-LO. Cancer Res 1988; 48:2993-2997.
53. Verberne HJ, de Bruin K, Habraken JB, et al. No-carrier-added versus carrier-added123I-metaiodobenzylguanidine for the assessment of cardiac sympathetic nerve activity. Eur J Nucl Med Mol Imaging 2006; 33:483-490.
54. Mairs RJ, Russell J, Cunningham S, et al. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma. Eur J Cancer 1995; 31A:576-581.
55. Barrett JA, Joyal JL, Hillier SM, et al. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution. Cancer Biother Radiopharm 2010; 25:299-308.
56. Matthay KK, Weiss B, Villablanca JG, et al. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: New approaches to neuroblastoma therapy consortium trial. J Nucl Med 2012; 53:1155-1163.
57. Garaventa A, Gambini C, Villavecchia G, et al. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine. Cancer 2003; 97:1332-1338.
58. Polishchuk AL, Dubois SG, Haas-Kogan D, et al. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. Cancer 2011; 117:4286-4293.
59. DuBois SG, Messina J, Maris JM, et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 2004; 22:2452-2460.
60. Prise KM, O'Sullivan JM. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer 2009; 9:351-360.
61. Mothersill C, Seymour C. Radiation-induced bystander and other non-targeted effects: Novel intervention points in cancer therapy? Curr Cancer Drug Targets 2006; 6:447-454.
62. Bishayee A, Rao DV, Bouchet LG, et al. Protection by DMSO against cell death caused by intracellularly localized iodine-125, iodine-131 and polonium-210. Radiat Res 2000; 153:416-427.
63. Boyd M, Ross SC, Dorrens J, et al. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. J Nucl Med 2006; 47:1007-1015.
64. Smets LA, Bout B, Wisse J. Cytotoxic and antitumor effects of the norepinephrine analogue meta-iodo-benzylguanidine (MIBG). Cancer Chemother Pharmacol 1988; 21:9-13.
65. Mairs RJ, Angerson WJ, Babich JW, et al. Differential penetration of targeting agents into multicellular spheroids derived from human neuroblastoma. Prog Clin Biol Res 1991; 366:495-501.
66. Wang SS, Hsiao R, Limpar MM, et al. Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin. Int J Mol Med 2014; 33:35-42.
67. Gaze MN, Mairs RJ, Boyack SM, et al. 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. Br J Cancer 1992; 66:1048-1052.
68. Cornelissen J, Van Kuilenburg AB, Voûte PA, et al. MIBG causes oxidative stress and up-regulation of anti-oxidant enzymes in the human neuroblastoma cell line SK-N-BE(2c). Int. J Cancer 1997; 72:486-490.
69. Cornelissen J, Wanders RJ, Van den Bogert C, et al. Meta-iodobenzylguanidine (MIBG) inhibits malate and succinate driven mitochondrial ATP synthesis in the human neuroblastoma cell line SK-N-BE(2c) Eur. J Cancer 1995 31A:582-586.
70. DuBois SG, Matthay KK. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol 2008; 35:S35-48.
71. Montaldo PG, Carbone R, Cornaglia Ferraris P, et al. Interferon-γ-induced differentiation of human neuroblastoma cells increases cellular uptake and halflife of metaiodobenzylguanidine. Cytotechnology 1993; 11:S140-143.
72. Montaldo PG, Raffaghello L, Guarnaccia F, et al. Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells. Int J Cancer 1996; 67:95-100.
73. Rutgers M, Buitenhuis CK, Hoefnagel CA, et al. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: Tissue distribution, metabolism and therapeutic efficacy. Int J Cancer 2000; 87:412-422.
74. Matthay KK, Panina C, Huberty J, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 2001; 42:1713-1721.
75. Mairs RJ, Livingstone A, Gaze MN, et al. Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction. Br J Cancer 1994; 70:97-101.
76. Lode HN, Bruchelt G, Seitz G, et al. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of monoamine transporters in neuroblastoma cell lines: Correlations to meta-iodobenzylguanidine (MIBG) uptake and tyrosine hydroxylase gene expression. Eur J Cancer 1995; 31A:586-590.
77. Smets LA, Janssen M, Rutgers M, et al. Pharmacokinetics and intracellular distribution of the tumor-targeted radiopharmaceutical m-iodo-benzylguanidine in SK-N-SH neuroblastoma and PC-12 pheochromocytoma cells. Int J Cancer 1991; 48:609-615.
78. Höpfner M, Sutter AP, Huether A, et al. A novel approach in the treatment of neuroendocrine gastrointestinal tumors: Additive antiproliferative effects of interferon-gamma and meta-iodobenzylguanidine. BMC Cancer 2004; 4:23.
79. Iavarone A, Lasorella A, Servidei T, et al. Uptake and storage of m-iodobenzylguanidine are frequent neuronal functions of human neuroblastoma cell lines. Cancer Res 1993; 53:304-309.
80. Montaldo PG, Carbone R, Ponzoni M, et al. gamma-Interferon increases metaiodobenzylguanidine incorporation and retention in human neuroblastoma cells. Cancer Res 1992; 52:4960-4964.
81. Sun Z, Fan Y, Zha Q, et al. Corticosterone up-regulates expression and function of norepinephrine transporter in SK-N-BE(2)C cells. J Neurochem 2010; 113:105-116.
82. Armour A, Cunningham SH, Gaze MN, et al. The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro. Br J Cancer 1997; 75:470-476.
83. Meco D, Lasorella A, Riccardi A, et al. Influence of cisplatin and doxorubicin on 125I-meta-iodobenzylguanidine uptake in human neuroblastoma cell lines. Eur J Cancer 1999; 35:1227-1234.
84. Mastrangelo R, Tornesello A, Riccardi R, et al. A new approach in the treatment of stage IV neuroblastoma using a combination of [131I]meta-iodobenzylguanidine (MIBG) and cisplatin. Eur J Cancer 1995; 31A:606-611.
85. Mastrangelo R, Tornesello A, Lasorella A, et al. Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma. J Neurooncol 1997; 31:153-158.
86. Apparsundaram S, Galli A, DeFelice LJ, et al. Acute regulation of norepinephrine transport: I. protein kinase C-linked muscarinic receptors influence transport capacity and transporter density in SK-N-SH cells. J Pharmacol Exp Ther 1998; 287:733-743.
87. Chung HW, Park JW, Lee EJ, et al. 131I-MIBG targeting of neuroblastoma cells is acutely enhanced by KCl stimulation through the calcium/calmodulin-dependent kinase pathway. Cancer Biother Radiopharm 2013; 28:488-493.
88. Mueller S, Yang X, Sottero TL, et al. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: Efficacy and underlying mechanisms. Cancer Lett 2011; 306:223-229.
89. More SS, Itsara M, Yang X, et al. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clin Cancer Res 2011; 17:2339-2349.
90. Rae C, Tesson M, Babich JW, et al. Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species. EJNMMI Res 2013; 3:73.
91. McCluskey AG, Boyd M, Ross SC, et al. [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter. Clin Cancer Res 2005; 11:7929-7937.
92. Nitschke R, Parkhurst J, Sullivan J, et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: A Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 1998; 20:315-318.
93. 131I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: A new approaches to neuroblastoma therapy trial. Clin Cancer Res 2012; 18:2679-2686.
94. McCluskey AG, Mairs RJ, Tesson M, et al. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter. J Nucl Med 2012; 53:1146-1154.
95. Mueller S, Bhargava S, Molinaro AM, et al. Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma. Anticancer Res 2013; 33:755-762.
96. Boyd M, Mairs RJ, Mairs SC, et al. Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill. Oncogene 2001; 20:7804-7808.
97. Cunningham S, Boyd M, Brown MM, et al. A gene therapy approach to enhance the targeted radiotherapy of neuroblastoma. Med Pediatr Oncol 2000; 35:708-711.
98. Doubrovin MM, Doubrovina ES, Zanzonico P, et al. In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene. Cancer Res 2007; 67:11959-11969.
99. McCluskey AG, Mairs RJ, Sorensen A, et al. Gamma irradiation and targeted radionuclides enhance the expression of the noradrenaline transporter transgene controlled by the radio-inducible p21(WAF1/CIP1) promoter. Radiat Res 2013; 179:282-292.